City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  412  Clinical trial(s) found  (Page 1 of 17 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 17496

Principal Investigator: Benjamin Djulbegovic, MD
Sponsor: NCI Approved External Peer Review

Title:  Evaluation of the Group Decision-making Process of Clinical Guidelines Panels

COH Protocol Number: 17493 ClinicalTrials.gov Number: NCT03201458

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  PHII-165, NCI#10139: A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

COH Protocol Number: 17457

Principal Investigator: Sunita Patel, PhD
Sponsor: Institutional

Title:  A Feasibility Study of Lifetime Stress and Effects on the Epigenome for Late-onset Breast Cancer Risk

COH Protocol Number: 17453 ClinicalTrials.gov Number: NCT03223753

Principal Investigator: Saro Armenian, DO
Sponsor: Cooperative Group

Title:  COG ALTE1631: A Randomized Web-based Physical Activity Intervention Among Children and Adolescents with Acute Lymphoblastic Leukemia

COH Protocol Number: 17450 ClinicalTrials.gov Number: NCT03008278

Principal Investigator: Joseph Chao, MD
Sponsor: NCI Approved External Peer Review

Title:  PHII-162, NCI#10066: A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)

COH Protocol Number: 17438 ClinicalTrials.gov Number: NCT03365882

Principal Investigator: Marwan Fakih, MD
Sponsor: Cooperative Group

Title:  SWOG S1613: A Randomized Phase II Study Of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification

COH Protocol Number: 17436 ClinicalTrials.gov Number: NCT01871727

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma

COH Protocol Number: 17434 ClinicalTrials.gov Number: NCT03399799

Principal Investigator: Amrita Krishnan, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized GPRC5D x CD3 DuoBody® Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17422

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Feasibility of Longitudinal Blood Sample Collection in Patients Receiving Post Transplant Cyclophosphamide

COH Protocol Number: 17420 ClinicalTrials.gov Number: NCT03434379

Principal Investigator: Daneng Li, MD
Sponsor: Industrial

Title:  A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

COH Protocol Number: 17416 ClinicalTrials.gov Number: NCT03418961

Principal Investigator: Joanne Mortimer, MD
Sponsor: Cooperative Group

Title:  SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

COH Protocol Number: 17414 ClinicalTrials.gov Number: NCT02954991

Principal Investigator: Erminia Massarelli, MD, PhD
Sponsor: Industrial

Title:  A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

COH Protocol Number: 17405 ClinicalTrials.gov Number: NCT03430011

Principal Investigator: Myo Htut, MD
Sponsor: Industrial

Title:  Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma

COH Protocol Number: 17391 ClinicalTrials.gov Number: NCT03369964

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  A Phase Ib Study of the Safety and Pharmacology of Atezolizumab in Combination with an Immunotherapy Agent Investigated with or Without Anti-CD20 Therapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

COH Protocol Number: 17389 ClinicalTrials.gov Number: NCT02180711

Principal Investigator: Robert Chen, MD
Sponsor: Industrial

Title:  An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent B-cell Non-Hodgkin Lymphoma

COH Protocol Number: 17386 ClinicalTrials.gov Number: NCT03318939

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

COH Protocol Number: 17385

Principal Investigator: Maria Hahn, PhD
Sponsor: Institutional

Title:  Development of an Epigenetic Biomarker Panel for DCIS Invasiveness

COH Protocol Number: 17384 ClinicalTrials.gov Number: NCT03274492

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

COH Protocol Number: 17379 ClinicalTrials.gov Number: NCT03411915

Principal Investigator: Warren Chow, MD
Sponsor: Industrial

Title:  A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors

COH Protocol Number: 17378 ClinicalTrials.gov Number: NCT03033576

Principal Investigator: Kim Margolin, MD
Sponsor: Cooperative Group

Title:  SWOG S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent

COH Protocol Number: 17365 ClinicalTrials.gov Number: NCT03374085

Principal Investigator: Chatchada Karanes, MD
Sponsor: Industrial

Title:  A Phase 1 Multicenter, Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 17363 ClinicalTrials.gov Number: NCT03331562

Principal Investigator: Vincent Chung, MD
Sponsor: Institutional

Title:  A SU2C Catalyst Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda) With or Without a Vitamin D Receptor Agonist Paricalcitol (Zemplar) in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (With no Further Improvement in Their Tumor)

COH Protocol Number: 17361

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  Long-Term Follow-up Protocol for Subjects Treated with a CAR T-Cell Product on a Juno-Sponsored Clinical Trial

COH Protocol Number: 17353 ClinicalTrials.gov Number: NCT03267433

Principal Investigator: Robert Chen, MD
Sponsor: Cooperative Group

Title:  ECOG-ACRIN EA4151: Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

COH Protocol Number: 17352 ClinicalTrials.gov Number: NCT03374254

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants with Metastatic Colorectal Cancer (KEYNOTE-651)

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.